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ABSTRACT
Introduction Angiosarcoma is a rare and aggressive 
malignancy with a high metastatic potential and 
recurrence rate. Despite optimal treatment with surgery, 
with or without radiation, the prognosis remains poor 
and, therefore, new treatment strategies are warranted. 
Recently, propranolol has effectively been repurposed for 
the treatment of infantile haemangioma. Propranolol is 
a β3- sparing antagonist of the β-adrenergic receptor. In 
infantile haemangioma, the β1, β2 and β3 receptors are 
highly expressed. Angiosarcoma has several similarities 
with haemangioma, including its high β-adrenergic 
receptor expression and the supposedly important role of 
vascular endothelial growth factor in malignant growth. As 
a result, propranolol has been administered small scale 
in individual angiosarcoma cases with promising results. 
The precise effect of propranolol, however, is not yet 
established.
Methods and analysis The goal of this neoadjuvant window 
of opportunity study is to prospectively evaluate the activity 
of propranolol monotherapy in patients with cutaneous 
angiosarcoma. The neoadjuvant setting provides a good 
opportunity to rapidly evaluate both the clinical response 
and histological response, without a significant delay in 
standard anticancer treatment. Fourteen patients with 
primary, recurrent or metastatic cutaneous angiosarcoma 
will be included. Propranolol will be administered orally in 
an escalating dose during 3–6 weeks, before the initiation 
of standard treatment. The primary endpoint is clinical 
response according to Response Evaluation Criteria in Solid 
Tumours, as measured on consecutive coloured photographs 
or CT/MRI. The histological response will be determined as 
secondary endpoint, comparing the difference in proliferation 
index before and after propranolol by measuring the change 
in immunohistochemistry staining of Ki-67. The study will 
be considered positive when at least three patients have a 
response to propranolol.
Ethics and dissemination Ethical approval was obtained 
from the Medical Ethical Committee of the Netherlands 
Cancer Institute. Independent of the outcome, results of 
this study will be shared and submitted for publication in 
an international peer- reviewed journal.
Trial registration number NL8118; registry through the 
Netherlands Trial Register.
INTRODUCTION
Angiosarcoma is a rare and aggressive malig-
nancy with a high metastatic potential. The 
estimated incidence of angiosarcoma is 0.4 
per million patients per year, making it a 
very rare disease.1 The standard of care for 
localised angiosarcoma is currently complete 
surgical resection with or without radiation. 
Unfortunately, despite the current standard 
of care, only 60% of patients with localised 
disease survive for more than 5 years.2 Physi-
cians and researchers are, therefore, in 
urgent need to find better treatment options 
for these patients.
Various additional drugs for systemic 
treatment have been investigated before.2–4 
Although the role of (neo)adjuvant chemo-
therapy remains controversial for localised 
disease, neoadjuvant chemotherapy is often 
administered for locally advanced angiosar-
coma.3 5–8 Several cytotoxic drugs, including 
anthracyclines, taxanes and gemcitabine, 
Strengths and limitations of this study
 ► The neoadjuvant setting provides the opportuni-
ty to evaluate the antitumor response of propran-
olol monotherapy without delaying the standard 
treatment.
 ► The propranolol dose will be escalated to optimise 
the safety profile of the treatment.
 ► As it is a window of opportunity study, the study du-
ration will be relatively short.
 ► A limitation of the current design (proof of principle 
study) is the absence of randomisation.
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have shown activity in angiosarcoma in the locally 
advanced and metastatic setting, with overall response 
rates varying from 17% to 89%.2–4 However, for the treat-
ment of resectable angiosarcoma, none of the previous 
studies shows a prolonged disease- free survival or overall 
survival.3 5–10 Improved treatment in the neoadjuvant 
setting might reduce the local and distant recurrence 
rates by treating micrometastases at an early stage and by 
improving the resection margins, potentially leading to 
higher survival rates. As a result, new drugs are urgently 
needed to prolong the survival.
Propranolol hydrochloride, a synthetic β3- sparing- 
adrenergic receptor antagonist, was registered by the 
Food and Drug Agency decades ago for the treatment of 
hypertension. Drug repurposing is a drug development 
strategy focused on the reuse of existing drugs for new 
medical indications. Recently, propranolol has been 
repurposed and is now used in the treatment of infan-
tile haemangioma. Infantile haemangioma is a benign 
vascular tumour and propranolol dosed 3 mg/kg led 
to a complete to near- complete resolution in approxi-
mately 88% of the treated infants with infantile haeman-
gioma.11 12 The pharmacological effects of propranolol in 
infantile haemangioma are presumed to cause vasocon-
striction, a decreased expression of vascular endothelial 
growth factor (VEGF) and basic fibroblast growth factor, 
inhibition of migration and proliferation of tumour 
cells and induction of apoptosis of endothelial cells.12–16 
Angiosarcoma have several similarities with infantile 
haemangioma, including its high β-adrenergic receptor 
expression and the suggested important role of VEGF in 
malignant growth.14 17 18
Several small case reports and case series have confirmed 
the idea that propranolol could be repurposed to treat 
angiosarcoma. In these case reports, patients with locally 
advanced or metastatic angiosarcoma were treated with 
propranolol, in combination with various chemotherapy 
regimens, including combination therapy with cyclophos-
phamide, etoposide, paclitaxel and vinblastine- based 
chemotherapy. The dose of propranolol in combination 
therapy varied between 80 mg and 120 mg per day.19–24 In 
one case, there was a response after 1 week of propranolol 
monotherapy 40 mg two times per day.22 These doses of 
propranolol are much lower than the standard mainte-
nance dose of 160–320 mg daily for patients with hyper-
tension.25 Furthermore, there was a reduction in the 
proliferative index of 34%, stabilisation of tumour growth 
and less necrosis.22 Additionally, one case described a 
patient with metastatic cardiac angiosarcoma who showed 
a long- term response (>12 months) to propranolol mono-
therapy, while the mean survival time is only 4 months.26
Since literature regarding the activity and mode of 
action of propranolol as a single agent for angiosarcoma 
is scarce, our aim is to evaluate the activity of propran-
olol monotherapy in patients with primary, recurrent or 
metastatic cutaneous angiosarcoma before they proceed 
to their standard anticancer treatment. The neoadjuvant 
setting provides a good opportunity to rapidly evaluate 
both the clinical and histological responses, without 
delaying the standard anticancer treatment. Additional 
advantages of propranolol therapy would be the ease of 
use and the relatively mild toxicity profile. If this study 
turns out to be positive, further (randomised) clinical 
trials are thereby substantiated and highly recommended.
METHODS AND ANALYSIS
Aim and objectives
The aim of this study is to investigate the effect of neoad-
juvant propranolol monotherapy in patients with primary, 
recurrent or metastatic cutaneous angiosarcoma, before 
they proceed to their standard anticancer treatment (eg, 
isolated limb perfusion, chemotherapy, targeted therapy, 
surgical resection or radiotherapy). The primary objec-
tive is to determine the clinical response of propranolol 
monotherapy and the histologic response will be evalu-
ated as secondary objective.
Study design and study treatment
This is a prospective proof of principle study with neoad-
juvant propranolol monotherapy in patients with cuta-
neous angiosarcoma. We will use the neoadjuvant window 
as an opportunity to explore the activity of propranolol 
monotherapy, without delaying the standard treatment. 
The duration of treatment will be 3–6 weeks. In this single 
arm trial, patients with angiosarcoma will be treated with 
propranolol monotherapy in an intrapatient escalating 
dose, which will be adjusted to the tolerability of propran-
olol. The treatment plan of propranolol is provided in 
table 1. The treatment plan was designed based on doses 
used in the previous literature15 21 24 26 and not exceeding 
the maximum maintenance dose of 320 mg/day for the 
registered indication hypertension (maximum daily 
dose in our study 240 mg/day).25 In case of hypotension 
(blood pressure <90/60 mm Hg) or bradycardia (heart 
rate <55 bpm) or symptoms of bradycardia or hypoten-
sion (dizziness, syncope), the dose will be reduced to 
the previous dose level. In case of serious bradycardia 
(heart rate <50 bpm), the treatment will be stopped 
until an acceptable heart rate (>55 bpm) is reached and 
Table 1 Propranolol treatment plan
Dose escalation scheme
Period Dose level Dose
Day 1–day 7 1* 2 x/day 40 mg
Day 8–day 14 2* 2 x/day 80 mg
Day 15–day of surgery 
or biopsy 3* 3 x/day 80 mg
Tapering off scheme after surgery/biopsy
Period Dose
Day 1–day 7 2 x/day 80 mg
Day 8–day 14 2 x/day 40 mg
*All patients start on day 1 with dose level 1.
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propranolol will be restarted in the dose of the previous 
level.
The tolerability will be assessed during weekly visits in 
the outpatient clinic (figure 1). Each visit consists of a 
physical examination, blood draw for safety assessment 
(haematology, hepatic function and renal function), vital 
signs, ECG, toxicity assessment, concomitant medication 
registration and tumour response assessment. After the 
study treatment, a biopsy will be obtained to evaluate 
the histologic response to propranolol monotherapy. 
Propranolol will be tapered off after the biopsy to prevent 
withdrawal symptoms (table 1).
Patient selection
The study population consists of patients with primary, 
recurrent or metastatic cutaneous angiosarcoma, 
including angiosarcoma of the breast (radiation 
induced). Only patients with cutaneous angiosarcoma 
can participate, since these tumours are easily measur-
able on coloured photographs for clinical response evalu-
ation. Patients are eligible if they are at least 18 years old; 
have a good performance status (WHO- PS of 0–2); have 
an adequate blood count, kidney and renal function; have 
a window of at least 3 weeks between their diagnosis and 
the start of the standard anticancer treatment and have 
evaluable disease according to the Response Evaluation 
Criteria in Solid Tumours (RECIST) 1.1 criteria. Patients 
with primary visceral angiosarcoma, contraindications for 
β-blockade therapy or current treatment with β-blockade 
therapy (both selective and non- selective β-blockade ther-
apies) or other anticancer treatments are excluded.
Sample size calculation
An exact single- stage phase II design will be used with a 
one- sided significance level α of 0.05 and a power of 80%. 
The maximum response rate that would be of no interest 
was assumed to be 5% and the minimum required 
response rate was 30%. A total of 14 patients will be 
included in the study. If 3 or more out of these 14 patients 
have a response as defined in the study endpoints, the 
study is considered positive.
Study endpoints
Primary endpoint
The clinical response will be determined according to 
RECIST 1.1 criteria (progressive disease (PD) is >20% 
increase in size, partial response (PR) is >30% decrease 
in size, stable disease (SD) is in between while complete 
response (CR) is no measurable disease).27 A response 
is defined as CR, PR or SD with an improvement in clin-
ical characteristics, like thickness, erythaema, necrosis 
or oedema of the inflicted area. Documentation will be 
performed with colour photography, including a ruler 
to measure the size of the lesion. Radiologic assessment 
will only be done if the patient has radiologic evaluable 
disease at the beginning of the study treatment. If the 
study turns out to be positive, this treatment modality 
is highly interesting and should be tested further in a 
randomised trial.
Secondary endpoint
The histologic response on propranolol treatment is 
defined as difference in proliferation index. This will be 
assessed by measuring the change in immunohistochem-
istry staining of Ki-67 and the tumour activity between 
the posttreatment biopsy (obtained during surgery if 
applicable) and the diagnostic biopsy before the study 
treatment. A decrease of >30% of the Ki-67 staining will 
be considered as a positive histologic response.
Exploratory endpoints
To obtain additional data regarding the primary objec-
tives, the percentage of adrenergic receptors (β1- AR, 
β2- AR, β3- AR) in the pretreatment biopsies will be 
measured with immunohistochemically staining and the 
correlation with the antitumour response of the patients 
with angiosarcoma will be investigated.13 22 With this 
correlation analysis, the predictive value of adrenergic 
Baseline Study treatment 3-6 weeks Standard treatment
Tapering off
propranolol
 Weekly study assessments:
 - Physical examination
 - Laboratory exams
 - ECG
 - Tumour measurement
Start 
propranolol
- Informed consent
- Biopsy
- Physical exam
- Laboratory exams
- ECG
- Tumour measurement
Figure 1 Study assessments. An overview of the study assessments, which are planned at baseline, during study treatment or 
when the standard treatment is initiated.
4300.7802.430. Protected by copyright.
 o
n
 Septem
ber 23, 2020 at Erasm
us M
edical / X51
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2020-039449 on 10 September 2020. Downloaded from 
4 Heinhuis KM, et al. BMJ Open 2020;10:e039449. doi:10.1136/bmjopen-2020-039449
Open access 
receptor expression in tumour tissue on the antitumour 
response will be assessed. Finally, we will compare the 
PET response before start of treatment and at the end 
of propranolol treatment.
Study logistics
Patient recruitment and study duration
Treating physicians will identify patients as possible candi-
dates and inform patients about the study. If patients agree 
to participate and fulfil the selection criteria, patients 
will be included during an outpatient clinic visit. As this 
is a monocentre study, all patients will be included in 
the Netherlands Cancer Institute (NKI). Approximately 
20 new patients with angiosarcoma are seen in the NKI 
yearly. As a result, the expected duration of the study is 
2 years. Enrolment started on 27 December 2019.
Safety assessments
All adverse events will be recorded in the electronic 
case report forms (eCRF) during the weekly outpatient 
clinic visits. We will perform extra blood draws, ECGs and 
measurements of the vital signs during these visits for 
safety assessments. The recording of the adverse events 
will be done according to the National Cancer Institute 
Common Toxicity Criteria for Adverse Events V.5.0.
Data management
The original results will also be recorded in the eCRF by 
the investigators of the study. The data entry will be super-
vised by the Clinical Research Monitor.
Study monitoring
Monitoring of the study will be performed according to 
International Conference on Harmonisation Good Clin-
ical Practie (ICH GCP) by the Clinical Research Monitor 
of the NKI or the person to whom the monitoring tasks 
have been delegated. Among others, the following will 
be reviewed: compliance with the protocol, ICH GCP 
and all applicable regulatory requirements; consent 
procedures, including date of consent and signatures; 
study progress; (serious) adverse events; completion of 
the (e)CRFs and verification of data against the source 
data; and storage, dispensing and accountability of study 
medication.
The Medical Ethical Committee of the NKI will review 
the study every year throughout the complete study dura-
tion. During this review, the committee will focus on moni-
toring of the safety of patients and evaluate the balance 
between the efficacy and the harmfulness of propranolol.
Termination of the study
An interim analysis is planned after the treatment of seven 
patients. If there are already three or more responses 
at this time point, the study will be stopped and stated 
positive. Otherwise an additional seven patients will be 
included. Results of the study will be shared and submitted 
for publication in an international peer- reviewed journal.
Patient and public involvement
The trial protocol and other trial documents were devel-
oped in collaboration with the Dutch sarcoma patient 
advocacy group. They evaluated the specific patient need 
for this trial. They fully support this trial and the concept 
of exploring drug- repurposing strategies to improve 
outcome in sarcoma. The patient advocacy group will be 
informed about the progress of the study and the study 
timelines.
The study is funded by a Belgian non- profit organisa-
tion: the Anticancer Fund. Their mission is to comple-
ment current cancer care with patient- first thinking and 
a focus on evidence- based potential for new treatments. 
Financially, the Anticancer Fund is completely dependent 
on donations and private funding. The Anticancer Fund 
supports diverse clinical trials, mainly in underprioritised 
treatment groups (such as in rare tumours), with non- 
conventional therapies and repurposed drugs.
ETHICS AND DISSEMINATION
Ethical approval was obtained from the Medical Ethical 
Committee of the Netherlands Cancer Institute. Indepen-
dent of the outcome, results of this study will be shared 
and submitted for publication in an international peer- 
reviewed journal.
All essential documents (including patient files, the 
Investigator Study File, CRFs and electronic study data), 
data management and statistical files will be kept for 15 
years.
SUMMARY
Angiosarcoma is an extremely rare and aggressive malig-
nancy with a high metastatic potential and a dismal 
prognosis. The current standard treatment cannot suffi-
ciently manage the disease. Therefore, new strategies are 
warranted. Drug repurposing is a process of developing 
approved drugs for new medical indications. A strong 
rationale for repurposing of propranolol for the treat-
ment of angiosarcoma patients exists. The precise effect 
of propranolol monotherapy is not yet established. In this 
study, we will therefore address the question about the 
efficacy of propranolol as neoadjuvant monotherapy in 
patients with cutaneous angiosarcoma. If this study shows 
positive results, further clinical trials are needed to estab-
lish the role of propranolol in the treatment of angiosar-
coma, possibly even in combination with other agents such 
as chemotherapy, targeted therapy or immunotherapy.
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